This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Centene Corporation is a well-diversified, multi-national healthcare company that primarily provides a set of services to the government sponsored healthcare programs. The company serves the under-insured and uninsured individuals through member-focused services. It is also engaged in providing education and outreach programs to inform and assist members in accessing quality, appropriate healthcare services. Centene is now a $100-billion plus enterprise catering healthcare services to more than 24 million members across 50 states. The recent acquisition of WellCare Health leveraged the company’s position as the largest Medicaid managed care organization in the country. The combined entity now has 22 million members. In 2019, the company retained its market-leading position nationwide, serving 1.8 million exchange members across 20 states at the year-end.
Why Molina Appears an Attractive Stock for Your Portfolio
by Zacks Equity Research
Riding high on a robust revenue stream and solid streamlining measures, Molina (MOH) holds immense potential to garner benefits for investors.
Centene (CNC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Centene (CNC) closed at $54.19, marking a +0.56% move from the previous day.
Is Centene (CNC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should John Hancock Multifactor Mid Cap ETF (JHMM) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for JHMM
Centene (CNC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Centene (CNC) closed at $56.23, marking a +0.25% move from the previous day.
Add These 4 Low Price-to-Cash Flow Stocks for Better Gains
by Sumit Singh
The metric evaluates the market price of a stock relative to the amount of cash flow that the company is generating on a per-share basis, the lower the number, the better.
Why Should You Hold Centene (CNC) in Your Portfolio Now?
by Zacks Equity Research
Banking on a robust revenues and strategic initiatives, Centene (CNC) has immense potential to reap benefits for investors.
Why Is Centene (CNC) Up 13.1% Since Last Earnings Report?
by Zacks Equity Research
Centene (CNC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medtronic (MDT) to Report Q4 Earnings: Will It Top Estimates?
by Zacks Equity Research
We are upbeat about Medtronic's (MDT) successful execution of growth strategies such as therapy innovation, globalization and increase in economic value.
Is Centene (CNC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Reasons Growth Investors Will Love Centene (CNC)
by Zacks Equity Research
Centene (CNC) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Value Investing Set to Shine: 5 Top-Ranked ETFs & Stocks
by Sweta Killa
Value investing seek to capitalize on inefficiencies in the market and have the potential to deliver higher returns with lower volatility compared with growth and blend counterparts.
Ensign Group (ENSG) Q1 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
Ensign Group's (ENSG) first-quarter earnings increase owing to a robust revenue stream.
MEDNAX (MD) Q1 Earnings Miss Estimates, Decline Y/Y
by Zacks Equity Research
MEDNAX's (MD) first-quarter earnings disappoint with weak revenues and elevated expenses.
Teladoc Health (TDOC) Surpasses Estimates in Q1 Earnings
by Zacks Equity Research
Teladoc's (TDOC) loss in the first quarter can be attributed to higher operating expenses than revenues.
Cigna (CI) Beats Q1 Earnings Estimates, Raises 2019 View
by Zacks Equity Research
Cigna (CI) beats Q1 earnings estimates on revenue growth driven by the acquisition of Express Scripts.
Top Ranked Growth Stocks to Buy for May 2nd
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, May 2nd
Humana (HUM) Q1 Earnings & Revenues Beat Estimates, SurgeY/Y
by Zacks Equity Research
Humana's (HUM) first-quarter earnings benefit from Medicare Advantage membership growth and robust revenues.
WellCare Health (WCG) Q1 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
WellCare Health's (WCG) first-quarter earnings gain from the acquisition of Meridian and organic growth.
Community Health (CYH) Incurs Wider-Than-Expected Loss in Q1
by Zacks Equity Research
Community Health's (CYH) first-quarter earnings suffer due to lower admissions.
HCA Healthcare's (HCA) Q1 Earnings Beat Estimates, Up Y/Y
by Zacks Equity Research
HCA Healthcare's (HCA) first-quarter earnings gain traction from higher revenues and better admissions.
Molina (MOH) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Molina's (MOH) first-quarter earnings benefit from lower expenses.
Tenet Healthcare (THC) Q1 Earnings Beat Estimates, Down Y/Y
by Zacks Equity Research
Tenet Healthcare's (THC) first-quarter earnings gain from strategic operational initiatives.
Should Value Investors Buy Centene (CNC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Centene (CNC) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Centene (CNC) is well positioned to outperform the market, as it exhibits above-average growth in financials.